Sedation/colonoscopy Surgery Sedation/colonoscopy
Conditions
Interventions
Patients in both groups initially received intravenously (IV) 2 mg (less than 70 kg body weight [b.w.]) or 3 mg (greater than 70 kg b.w.) of midazolam and 25 mg of pethidine. Additional midazolam was
Sponsors
Venizelion General Hospital of Heraklion (Greece)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 50 years and older, either sex 2. Undergoing colonoscopy for colorectal cancer (CRC) screening, postpolypectomy surveillance, or other indications for which the primary goal of the examination was detection of neoplasia
Exclusion criteria
Exclusion criteria: 1. Polyposis syndromes 2. Hereditary nonpolyposis CRC 3. Previous surgical resection of the colon or rectum 4. Active anticoagulation 5. Inflammatory bowel disease 6. Cases with inadequate bowel preparation 7. Incomplete colonoscopy 8. Cases where the desired level of sedation was not achieved or the level of unintended level of deep sedation occurred
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Polyp detection rate, measured at end of study | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at end of study: 1. Patients' and the endoscopist?s satisfaction 2. Recovery time 3. Adverse events related to sedation | — |
Countries
Greece
Outcome results
None listed